2012-03-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/687222摘要：慢性阻塞性肺疾病（COPD）是一個重大的公共衛生問題，主要是由吸煙所引起的。2004 年，慢性阻塞性肺病導致每年275 萬例死亡，佔全世界首要死亡原因第四位。在過去的幾十年，儘管吸煙率下降，慢性阻塞性肺病所造成的死亡仍是大幅上升。慢性阻塞性肺病無法治癒，治療只能緩解症狀。預防和開發新方法來治療慢性阻塞是迫切需要的。儘管慢性阻塞性肺病是一種常見的疾病，而且也消耗大量的醫療開支（2005年約 2400 萬新台幣），但是前瞻性的全國性的流行病學研究或臨床試驗是缺乏的。台灣慢性阻塞性肺病聯盟（TCoC）是由多位胸腔科的專家所組成，他們在慢性阻塞性肺病的領域有豐富的基礎實驗和臨床研究經驗。 TCoC 重要任務將是協助設計和進行多中心（研究者或國際研究組織與藥廠發起的）臨床試驗，以及建立慢性阻塞性肺病患者的資料庫。中心辦公室將提供通訊聯絡，資料庫維護和核心研究的協調窗口。 TCoC核心設施也會將提供臨床研究者進行候選基因的SNP 分析。參與者需要簽署知情同意書來提供臨床資訊，血液/血漿/血清/灌洗液存儲和基因SNP 分析。台灣慢性阻塞性肺病聯盟有能力每年招收大約700-800 慢性阻塞性肺病患者（從每家醫院大約每年100-120 例）。病人的臨床資料會使用網路建置的系統加以收集供日後分析使用。 TCoC最終的目標是推動有治療潛力的慢性阻塞性肺病臨床試驗，並加速治療方法發展的速度，使慢性阻塞性肺病患者的壽命得以延長，生活品質獲得改善。<br> Abstract: Chronic obstructive pulmonary disease (COPD) is a major public health problemmainly caused by cigarette smoking. In 2004, COPD causes 2.75 million deathsannually, representing the fourth leading cause of death worldwide. Mortality dueto COPD has risen sharply over the past several decades despite a major decline insmoking prevalence. There is no cure for COPD, and treatments are only moderatelyeffective at relieving symptoms. Novel approaches for prevention and treatmentof COPD are urgently needed. Although COPD is a common disease in ourpopulation and consumes a large amount of health care expenditure (about 2400million NTD in 2005), studies regarding longitudinal, prospective nationwideepidemiology, or intervention are lacking. The participating investigators ofTaiwan COPD consortium (TCoC) are specialists of pulmonary medicine who haveexperience in conducting bench and clinical studies of COPD. The key missions of theTCoC will be to assist the design and conduct of multi-center (investigator-initiated,industry or international research groups) clinical trials, as well as the establishment ofbiospecimen database of COPD patients. Central office will provide the window ofcommunication, database maintenance and core study coordination. The core facilityof TCoC will provide candidate genes SNP analysis under a collaborative clinicalresearch. Participating subjects need to sign the informed consent for clinical data ,PBMC/plasma/serum/ lavage fluids storage and gene SNP analysis. By estimation,the consortium has the ability to enroll 700-800 COPD patients per year (100-120patients from each site per year). Core clinical information will be collected using aweb based information system for future analysis. The ultimate goal for TCoC is toenable clinical trials of potential therapies for COPD and speed the development oftreatments that will improve the length and quality of life for patients with COPD.慢性阻塞性肺病COPD (Chronic obstructive pulmonary disease)